Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cannara Biotech Inc (OP: LOVFF )

0.6036 +0.0666 (+12.40%)
Streaming Delayed Price Updated: 11:19 AM EDT, May 17, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 22,000
Open 0.6000
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.5370
Today's Range 0.5946 - 0.6036
52wk Range 0.5370 - 0.8398
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Cannara Biotech Reports 51% YoY Revenue Increase In Q2, Wider Net Loss
Cannara Biotech Inc. announced on Monday its fiscal second quarter 2024 financial and operating results for the three and six-month periods ended Feb. 29, 2024. The company reported a 68%... 
Via Benzinga
Topics Cannabis
Exposures Cannabis
This Cannabis Producer Reports It Is Able to Deliver Some Of The Highest Quality Product To Market At Some Of The Most Competitive Prices
--News Direct-- 
Via News Direct
Topics Cannabis
Exposures Cannabis

Performance

YTD
-3.36%
-3.36%
1 Month
+2.72%
+2.72%
3 Month
-6.62%
-6.62%
6 Month
-7.38%
-7.38%
1 Year
-5.47%
-5.47%

More News

Read More
The 7 Most Undervalued Cannabis Stocks to Buy in December
Via InvestorPlace
Topics Cannabis
Exposures Cannabis
This Cannabis Producer Reports It Is Able to Deliver Some Of The Highest Quality Product To Market At Some Of The Most Competitive Prices
Via Benzinga
Topics Cannabis
Exposures Cannabis
Bearish Sentiment Across The Cannabis Space - Check Full Movers For August 21, 2023
Via Benzinga
Topics Cannabis
Exposures Cannabis
7 Smoking-Hot 420 Stocks to Buy in 2023
Via InvestorPlace
Topics Cannabis
Exposures Cannabis
Cannabis Stock Movers For August 10, 2023
Via Benzinga
Topics Cannabis
Exposures Cannabis
Cannara Biotech Q3 FY23 Net Revenue Grows 57% YoY, What About Adjusted EBITDA?
Via Benzinga
Cannabis Stock Gainers And Losers From July 25, 2023
Via Benzinga
Cannabis Stock Gainers And Losers From August 4, 2023
Via Benzinga
Cannara Biotech Secures An Additional $10M In Non-Dilutive Capital With Its Lead Credit Provider, BMO Commercial Banking
Via Benzinga
Cannara Biotech Q2 FY23 Revenue Grows 76% YoY To $9.6M, Here Are The Details
Via Benzinga
Marijuana Stock Movers For August 1, 2023
Via Benzinga
Olymbec Investments Increases Its Ownership In Cannara Biotech
Via Benzinga
Cannara Biotech Q1 Revenue Grows 57% YoY To $7.7M, What About Adjusted EBITDA?
Via Benzinga
Cannabis Stock Movers For July 27, 2023
Via Benzinga
Cannara Biotech Q4 Revenue Grows 84% YoY To $8.9M
Via Benzinga
Cannara Biotech Enters Into The British Columbia Cannabis Market And Launches New Products
Via Benzinga
Cannara Biotech Signs An Exclusive Brand Partnership With Exotic Genetix In Canada
Via Benzinga
Cannara Biotech Revenue Grows 41% YoY, Here Are The Details
Via Benzinga
Cannara Biotech Closes $50 Million Credit Facility Led By BMO Commercial Banking
Via Benzinga
Cannara Biotech Revenues Grew 229% To $7.4M In Q2 2022 YoY
Via Benzinga
The Week In Cannabis: Isiah Thomas, Tilray, The DEA, Ohio, Mexico And More
Via Benzinga
Topics Cannabis
Exposures Cannabis
Cannara Biotech Shares Surge On 983% QoQ Revenue Growth, Positive Adjusted EBITDA
Via Benzinga
Topics Cannabis
Exposures Cannabis
Tilray Best Performer Among Canadian Cannabis LPs, Stocks Plunge Nearly 10% In July
Via Benzinga
Topics Cannabis
Exposures Cannabis
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.